Indigophoton
Senior Member (Voting Rights)
The latest 14min video research update from Ron Davis' group. Not a lot new, but a useful summary of where they are at.
https://www.omf.ngo/ron-davis-research-update-video/
RD says they have found fewer viruses in the (severely ill) patient group than in healthy people, which was the opposite of what he expected.
They are going to do a large analysis of blood to look for any kind of pathogen, based on looking for pathogen dna.
They have had a number of assorted issues to deal with and overcome to be able to use the nanoneedle effectively and reproducibly. They can now do two chips at once, eg a patient and a healthy control. They will probably build or source something that can do many chips at once.
They have studied 11 patients and 10 healthy controls: they are just about ready to publish the results, which have consistently differentiated patients from controls. They don't yet know why they get the results they get.
ME red blood cells are sticky in vitro and a little different in colour; more studies to be done.
They are very keen to find a biomarker and know how to go from lab to clinical test if the data they have pan out.
They would also like to distinguish ME/CFS from other diseases (as well as healthy controls) - some of the biochemistry looks a little like diabetes for instance - to make sure the correct treatments are applied.
https://www.omf.ngo/ron-davis-research-update-video/
RD says they have found fewer viruses in the (severely ill) patient group than in healthy people, which was the opposite of what he expected.
They are going to do a large analysis of blood to look for any kind of pathogen, based on looking for pathogen dna.
They have had a number of assorted issues to deal with and overcome to be able to use the nanoneedle effectively and reproducibly. They can now do two chips at once, eg a patient and a healthy control. They will probably build or source something that can do many chips at once.
They have studied 11 patients and 10 healthy controls: they are just about ready to publish the results, which have consistently differentiated patients from controls. They don't yet know why they get the results they get.
ME red blood cells are sticky in vitro and a little different in colour; more studies to be done.
They are very keen to find a biomarker and know how to go from lab to clinical test if the data they have pan out.
They would also like to distinguish ME/CFS from other diseases (as well as healthy controls) - some of the biochemistry looks a little like diabetes for instance - to make sure the correct treatments are applied.